Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891 is registered in ClinicalTrials.gov with Oana Danciu as lead sponsor.

NCT NCT05467891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05467891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Lead sponsor
Oana Danciu
Phase
Phase 2
Overall status
Recruiting
Start date
September 13, 2022
Completion date
August 15, 2029
Enrollment
200 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, hormone receptor-positive breast cancer, locoregional recurrence